Summary:
Evaluate the safety and tolerability of investigational study drug administered by subcutaneous (SQ) injection to adults with moderate to severe, active Crohn’s disease (CD) who have failed prior treatment with anti-tumor necrosis factor alpha (TNFα) agen.
Qualified Participants Must:
• Male or Females ages 18 to 65 years old
•
Has diagnosis of CD
•
Speak English fluently
•
Moderate to severe active CD